Furthermore, anti-tumor efficacy of VS-4718 was also dependent on CD8+ T cells, and SCC FAK-WT tumors treated with VS-4718 on a CD8+ T cell-depleted background exhibited a growth delay but did not undergo tumor regression (Figure 7I). Here, CD8A is linked to neoplasm.